Literature DB >> 27193470

Investigation of the human FCRL1, 2, and 4 gene expressions in patients with rheumatoid arthritis.

Ali Khanzadeh1, Zahra Habibagahi2, Ahmad Hosseini3, Zahra Amirghofran4,5.   

Abstract

The Fc receptor-like (FCRL) molecules have recently been shown to contribute to the pathogenesis of certain autoimmune disorders. In this study, we investigated the expression levels of FCRL1, 2 and 4 in blood mononuclear cells from rheumatoid arthritis patients using real-time PCR. The mRNA of these molecules was detected in 44.4 % (FCRL1), 53.3 % (FCRL2) and 31.1 % (FCRL4) of patients. Comparatively, 31.1 % (FCRL1), 51.1 % (FCRL2) and 26.6 % (FCRL4) of controls expressed these genes. Analysis of gene expressions in FCRL-positive patients demonstrated a lower FCRL4 gene expression in patients compared to controls (P < 0.001). In FCRL2-positive patients, a significant positive correlation between FCRL2 expression and the erythrocyte sedimentation rate (P < 0.001), anti-cyclic citrullinated peptide antibody (P = 0.033) level and disease activity score (DAS28, P = 0.016) was found. In conclusion, decreased FCRL4 expression and association of FCRL2 expression with inflammatory markers and disease activity suggested the contribution of these molecules to RA inflammatory processes.

Entities:  

Keywords:  Fc receptor-like molecules; Real-time PCR; Rheumatoid arthritis; mRNA

Mesh:

Substances:

Year:  2016        PMID: 27193470     DOI: 10.1007/s00296-016-3495-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Identification of a family of Fc receptor homologs with preferential B cell expression.

Authors:  R S Davis; Y H Wang; H Kubagawa; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features.

Authors:  Ludmila V Mechetina; Alexander M Najakshin; Olga Y Volkova; Sergei V Guselnikov; Rafik Z Faizulin; Boris Y Alabyev; Nikolai A Chikaev; Maria S Vinogradova; Alexander V Taranin
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

3.  Supportive evidence for a genetic association of the FCRL3 promoter polymorphism with rheumatoid arthritis.

Authors:  K Ikari; S Momohara; T Nakamura; M Hara; H Yamanaka; T Tomatsu; N Kamatani
Journal:  Ann Rheum Dis       Date:  2005-09-21       Impact factor: 19.103

4.  A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities.

Authors:  Yuta Kochi; Ryo Yamada; Akari Suzuki; John B Harley; Senji Shirasawa; Tetsuji Sawada; Sang-Cheol Bae; Shinya Tokuhiro; Xiaotian Chang; Akihiro Sekine; Atsushi Takahashi; Tatsuhiko Tsunoda; Yozo Ohnishi; Kenneth M Kaufman; Changsoo Paul Kang; Changwon Kang; Shigeru Otsubo; Wako Yumura; Akio Mimori; Takao Koike; Yusuke Nakamura; Takehiko Sasazuki; Kazuhiko Yamamoto
Journal:  Nat Genet       Date:  2005-04-17       Impact factor: 38.330

5.  Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.

Authors:  M J Simmonds; J M Heward; J Carr-Smith; H Foxall; J A Franklyn; S C L Gough
Journal:  J Clin Endocrinol Metab       Date:  2005-12-29       Impact factor: 5.958

6.  Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells.

Authors:  Noraidah Masir; Margaret Jones; Michela Pozzobon; Teresa Marafioti; Olga Y Volkova; Ludmila V Mechetina; Martin-Leo Hansmann; Yasodha Natkunam; Alexander V Taranin; David Y Mason
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

7.  FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells.

Authors:  Tanisha A Jackson; Christopher L Haga; Götz R A Ehrhardt; Randall S Davis; Max D Cooper
Journal:  J Immunol       Date:  2010-11-10       Impact factor: 5.422

8.  The inhibitory potential of Fc receptor homolog 4 on memory B cells.

Authors:  Gotz R A Ehrhardt; Randall S Davis; Joyce T Hsu; Chuen-Miin Leu; Annette Ehrhardt; Max D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

9.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

10.  Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis.

Authors:  L Yeo; H Lom; M Juarez; M Snow; C D Buckley; A Filer; K Raza; D Scheel-Toellner
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

View more
  4 in total

1.  Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients.

Authors:  Maryam Zarrabi; Mohammadali Nazarinia; Abbas Rahimi Jaberi; Nasser Gholijani; Zahra Amirghofran
Journal:  Med Princ Pract       Date:  2020-10-20       Impact factor: 1.927

2.  Identification of dysregulated genes in rheumatoid arthritis based on bioinformatics analysis.

Authors:  Ruihu Hao; Haiwei Du; Lin Guo; Fengde Tian; Ning An; Tiejun Yang; Changcheng Wang; Bo Wang; Zihao Zhou
Journal:  PeerJ       Date:  2017-03-15       Impact factor: 2.984

3.  Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma.

Authors:  Yu Liu; Yiding Chen; Xianyu Hu; Jialin Meng; Xiaojing Li
Journal:  Biomed Res Int       Date:  2020-08-22       Impact factor: 3.411

4.  Investigating the molecular control of deer antler extract on articular cartilage.

Authors:  Baojin Yao; Zhenwei Zhou; Mei Zhang; Xiangyang Leng; Daqing Zhao
Journal:  J Orthop Surg Res       Date:  2021-01-06       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.